



Moolec Science Secures Core U.S. Patent for Piggy Sooy™, Soybean Expressing up to 30% of Animal Protein

Warwick, United Kingdom. June 18, 2025. Moolec Science Limited a wholly-owned subsidiary of Moolec Science SA (NASDAQ: MLEC; “The Company”; “Moolec”), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its proprietary groundbreaking Piggy Sooy™ technology - soybean plant engineered to express high levels of porcine hemeproteins in their seeds.

Piggy Sooy™ is the first patented soybean technology designed to produce high levels of porcine hemeproteins directly in the seeds. The U.S. patent covers the plants and seeds, the method used to develop them, and food compositions derived from this breakthrough innovation. In April 2024, the USDA-APHIS confirmed the Piggy Sooy™ does not present plant pest risk difference from conventional soybeans, determining it is not subject to regulation under 7 CFR part 340 - a key regulatory milestone toward commercialization.

Moolec’s Chief Science Officer, Amit Dhingra, stated: *“Initial field trials demonstrated promising production yield, with over 20% animal protein content in the total soluble protein fraction. Furthermore, the deployment of Piggy Sooy™ technology presents compelling environmental benefits when compared to traditional agricultural and meat production practices. One acre of Piggy Sooy™ has the potential capacity to produce the same amount of protein as approximately 10 pigs, using ~35x less land, generating ~8x less water footprint and ~60x less CO₂ emissions. These multifaceted benefits make Piggy Sooy™ a game-changer in sustainable protein production.”*

This patent provides Moolec with exclusive commercial rights to Piggy Sooy™ technology in the U.S. until 2042, significantly strengthening the Company’s intellectual property portfolio. This is the first in a series of over fifteen patent applications filed globally aimed at protecting Moolec’s Molecular Farming innovations.

“Our experience has taught us that long-term success in biotechnology is built on securing robust, enforceable intellectual property. This patent validates Moolec’s scientific leadership in Molecular Farming and protects a technology with unprecedented levels of animal protein expression in plants. It’s not only a recognition of our innovation, but a vital asset that allows us to advance confidently toward commercialization and build a differentiated position in our food and feed ingredients business,” said Alejandro Antalich, CEO of Moolec Science.



About Moolec Science SA

Moolec Science is a science-driven food tech company pioneering Molecular Farming—a scalable and sustainable platform that uses plants as bioreactors to produce animal proteins and functional ingredients. Following its recent integration with key assets from the Bioceres Group and Nutrecon, Moolec now combines expertise in synthetic biology, plant genetics, and industrial biotechnology to develop next-generation ingredients for the food and agriculture industries. The Company’s expanded capabilities include proprietary crops, fermentation-based technologies, and advanced processing platforms, enabling a seed-to-ingredient approach that enhances functionality, nutrition, and sustainability. Moolec’s pipeline spans alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture. Through this integration, Moolec now benefits from a combined intellectual property portfolio of over 500 granted and pending patents across multiple technology platforms. The Company operates across the United States, South America, and Europe, and is listed on Nasdaq under the ticker “MLEC.” For more information, visit www.moolecscience.com and ir.moolecscience.com.

Forward Looking Statements

This press release contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information,



future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Moolec Science's Contacts

- Press & Media inquiries: comms@moolecscience.com
- Investor Relations inquiries: ir@moolecscience.com